Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors.
Dankner M, Wang Y, Fazelzad R, Johnson B, Nebhan CA, Dagogo-Jack I, Myall NJ, Richtig G, Bracht JWP, Gerlinger M, Shinozaki E, Yoshino T, Kotani D, Fangusaro JR, Gautschi O, Mazieres J, Sosman JA, Kopetz S, Subbiah V, Davies MA, Groover AL, Sullivan RJ, Flaherty KT, Johnson DB, Benedetti A, Cescon DW, Spreafico A, Zogopoulos G, Rose AAN. Dankner M, et al. Among authors: shinozaki e. JCO Precis Oncol. 2022 Aug;6:e2200107. doi: 10.1200/PO.22.00107. JCO Precis Oncol. 2022. PMID: 35977349 Free PMC article.
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I, Shinozaki E, Matsushima T, Wakatsuki T, Ogura M, Ichimura T, Ozaka M, Takahari D, Suenaga M, Chin K, Mizunuma N, Yamaguchi K. Nakayama I, et al. Among authors: shinozaki e. BMC Cancer. 2017 Jan 9;17(1):38. doi: 10.1186/s12885-016-2994-6. BMC Cancer. 2017. PMID: 28068936 Free PMC article.
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
Shinozaki E, Yoshino T, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shitara K, Bando H, Mimaki S, Nakai C, Matsushima K, Suzuki Y, Akagi K, Yamanaka T, Nomura S, Fujii S, Esumi H, Sugiyama M, Nishida N, Mizokami M, Koh Y, Abe Y, Ohtsu A, Tsuchihara K. Shinozaki E, et al. Br J Cancer. 2017 Nov 7;117(10):1450-1458. doi: 10.1038/bjc.2017.308. Epub 2017 Oct 3. Br J Cancer. 2017. PMID: 28972961 Free PMC article.
Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study''.
Shinozaki E, Yoshino T, Tsuchihara K. Shinozaki E, et al. Br J Cancer. 2018 May;118(9):1278-1279. doi: 10.1038/s41416-018-0040-y. Epub 2018 Mar 22. Br J Cancer. 2018. PMID: 29563632 Free PMC article. No abstract available.
Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer.
Osumi H, Shinozaki E, Wakatsuki T, Suenaga M, Ichimura T, Ogura M, Takahari D, Ooki A, Suzuki T, Ota Y, Nakayama I, Chin K, Miki Y, Yamaguchi K. Osumi H, et al. Among authors: shinozaki e. Int J Cancer. 2019 Nov 1;145(9):2488-2495. doi: 10.1002/ijc.32320. Epub 2019 May 7. Int J Cancer. 2019. PMID: 30963570 Free article.
Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer.
Masuishi T, Taniguchi H, Kotani D, Bando H, Komatsu Y, Shinozaki E, Nakajima TE, Satoh T, Nishina T, Esaki T, Wakabayashi M, Nomura S, Takahashi K, Ono H, Hirano N, Fujishiro N, Fuse N, Sato A, Ohtsu A, Yoshino T. Masuishi T, et al. Among authors: shinozaki e. ESMO Open. 2019 Nov 13;4(6):e000590. doi: 10.1136/esmoopen-2019-000590. eCollection 2019. ESMO Open. 2019. PMID: 31798981 Free PMC article.
REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer.
Nakajima H, Kotani D, Bando H, Kato T, Oki E, Shinozaki E, Sunakawa Y, Yamazaki K, Yuki S, Nakamura Y, Yamanaka T, Yoshino T, Ohta T, Taniguchi H, Kagawa Y. Nakajima H, et al. Among authors: shinozaki e. BMC Cancer. 2021 Jun 7;21(1):674. doi: 10.1186/s12885-021-08395-2. BMC Cancer. 2021. PMID: 34098908 Free PMC article.
165 results